# US 2003/0212008 A1 · Farnesyl protein transferase inhibitor combinations with further anti-cancer agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0212008 A1
- Document ID: US20030212008A1
- Status: Published application
- Kind: A1
- Application number: 10/220,219
- Filed: 2002-08-28
- Published: 2003-11-13
- Earliest claimed: 2000-02-29
- Inventors: Peter Albert Palmer; Ivan David Horak
- Web page: https://patentgrep.com/patent/US20030212008A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is concerned with combinations of a farnesyl transferase inhibitor and two or more further anti-cancer agents for inhibiting the growth of tumor cells and useful in the treatment of cancer.

## Claims

### Claim 1

A combination of a farnesyl transferase inhibitor selected from compounds of formulae (I), (II), (III), (IV), (V), (VI), (VII), (VIII) and (IX) below:
10
the pharmaceutically acceptable acid or base addition salts and the stereochemically isomeric forms thereof, wherein
the dotted line represents an optional bond;
X is oxygen or sulfur;
R1 is hydrogen, C1-12alkyl, Ar1, Ar2C1-6alkyl, quinolinylC1-6alkyl, pyridylC1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, aminoC1-6alkyl,
or a radical of formula -Alk1-C(═O)—R9, -Alk1-S(O)—R9 or -Alk1-S(O)2—R9, wherein Alk1 is C1-6alkanediyl,
R9 is hydroxy, C1-6alkyl, C1-6alkyloxy, amino, C1-8alkylamino or C1-8alkylamino substituted with C1-6alkyloxycarbonyl;
R2, R3 and R16 each independently are hydrogen, hydroxy, halo, cyano, C1-6alkyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy, aminoC1-6alkyloxy, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, Ar1, Ar2C1-6alkyl, Ar2oxy, Ar2C1-6alkyloxy, hydroxycarbonyl, C1-6alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C2-6alkenyl, 4,4-dimethyloxazolyl; or
when on adjacent positions R2 and R3 taken together may form a bivalent radical of formula
—O—CH2—O— (a-1), —O—CH2—CH2—O— (a-2), —O—CH═CH— (a-3), —O—CH2—CH2— (a-4), —O—CH2—CH2—CH2— (a-5), or —CH═CH—CH═CH— (a-6);
R4 and R5 each independently are hydrogen, halo, Ar1, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, hydroxycarbonyl, C1-6alkyloxycarbonyl, C1-6alkylS(O)C1-6alkyl or C1-6alkylS(O)2C1-6alkyl;
R6 and R7 each independently are hydrogen, halo, cyano, C1-6alkyl, C1-6alkyloxy, Ar2oxy, trihalomethyl, C1-6alkylthio, di(C1-6alkyl)amino, or
when on adjacent positions R6 and R7 taken together may form a bivalent radical of formula
—O—CH2—O— (c-1), or —CH═CH—CH═CH— (c-2);
R8 is hydrogen, C1-6alkyl, cyano, hydroxycarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonylC1-6alkyl, cyanoC1-6alkyl, C1-6alkyloxycarbonylC1-6alkyl, carboxyC1-6alkyl, hydroxyC1-6alkyl, aminoC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, imidazolyl, haloC1-6alkyl, C1-6alkyloxyC1-6alkyl, aminocarbonylC1-6alkyl, or a radical of formula
—O—R10 (b-1), —S—R10 (b-2), —N—R11R12 (b-3),
wherein
R10 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, Ar1, Ar2C1-16alkyl, C1-6alkyloxycarbonylC1-6alkyl, or a radical or formula -Alk2-OR13 or -Alk2-NR14R15;
R11 is hydrogen, C1-12alkyl, Ar1 or Ar2C1-6alkyl;
R12 is hydrogen, C1-6alkyl, C-16alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylaminocarbonyl, Ar1, Ar2C1-6alkyl, C1-6alkylcarbonyl-C1-6alkyl, a natural amino acid, Ar1carbonyl, Ar2C1-6alkylcarbonyl, aminocarbonylcarbonyl, C1-6alkyloxyC1-6alkylcarbonyl, hydroxy, C1-6alkyloxy, aminocarbonyl, di(C1-6alkyl)aminoC1-6alkylcarbonyl, amino, C1-6alkylamino, C1-6alkylcarbonylamino, or a radical or formula -Alk2-OR13 or -Alk2-NR14R15;
wherein
Alk2 is C1-6alkanediyl;
R13 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, hydroxyC1-6alkyl, Ar1 or Ar2C1-6alkyl;
R14 is hydrogen, C1-6alkyl, Ar1 or Ar2C1-6alkyl;
R15 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, Ar1 or Ar2C1-6alkyl;
R17 is hydrogen, halo, cyano, C1-6alkyl, C1-6alkyloxycarbonyl, Ar1;
R18 is hydrogen, C1-6alkyl, C1-6alkyloxy or halo;
R19 is hydrogen or C 16alkyl;
Ar1 is phenyl or phenyl substituted with C1-6alkyl, hydroxy, amino, C1-6alkyloxy or halo; and
Ar2 is phenyl or phenyl substituted with C1-6alkyl, hydroxy, amino, C1-6alkyloxy or halo.
11
the pharmaceutically acceptable acid or base addition salts and the stereochemically isomeric forms thereof, wherein
the dotted line represents an optional bond;
X is oxygen or sulfur;
R1 is hydrogen, C1-12alkyl, Ar1, Ar2C1-6alkyl, quinolinylC1-6alkyl, pyridylC1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, mono- or di (C1-6alkyl) aminoC1-6alkyl, aminoC1-6alkyl,
or a radical of formula -Alk1-C(═O)—R9, -Alk1-S(O)—R9 or -Alk1-S(O)2-R9,
wherein
Alk1 is C1-6alkanediyl,
R9 is hydroxy, C1-6alkyl, C1-6alkyloxy, amino, C1-8alkylamino or C1-8alkylamino substituted with C1-6alkyloxycarbonyl;
R2 and R3 each independently are hydrogen, hydroxy, halo, cyano, C1-6alkyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy, aminoC1-6alkyloxy, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, Ar1, Ar2C1-6alkyl, Ar2oxy, Ar2C1-16alkyloxy, hydroxycarbonyl, C1-6alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C2-6alkenyl; or
when on adjacent positions R2 and R3 taken together may form a bivalent radical of formula
—O—CH2—O— (a-1), —O—CH2—CH2—O— (a-2), —O—CH═CH— (a-3), —O—CH2—CH2— (a-4), —O—CH2—CH2—CH2— (a-5), or —CH═CH—CH═CH— (a-6);
R4 and R5 each independently are hydrogen, Ar1, C1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, hydroxycarbonyl, C1-6alkyloxycarbonyl, C1-6alkylS(O)C1-6alkyl or C1-6alkylS(O)2C1-6alkyl;
R6 and R7 each independently are hydrogen, halo, cyano, C1-6alkyl, C1-6alkyloxy or Ar2oxy;
R8 is hydrogen, C1-6alkyl, cyano, hydroxycarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonylC1-6alkyl, cyanoC1-6alkyl, C1-6alkyloxycarbonylC1-6alkyl, hydroxy-carbonylC1-6alkyl, hydroxyC1-6alkyl, aminoC1-6alkyl, mono- or di (C1-16alkyl)-aminoC1-6alkyl, haloC1-6alkyl, C1-6alkyloxyC1-6alkyl, aminocarbonylC1-6alkyl, Ar1, Ar2C1-6alkyloxyC1-6alkyl, C1-6alkylthioC1-6alkyl;
R10 is hydrogen, C1-6alkyl, C1-6alkyloxy or halo;
R11 is hydrogen or C1-6alkyl;
Ar1 is phenyl or phenyl substituted with C1-6alkyl, hydroxy, amino, C1-6alkyloxy or halo;
Ar2 is phenyl or phenyl substituted with C1-6alkyl,hydroxy,amino,C1-6alkyloxy or halo.
12
the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein
the dotted line represents an optional bond;
X is oxygen or sulfur;
-A- is a bivalent radical of formula
3 —CH═CH— (a-1), —CH2—CH2— (a-2), —CH2—CH2—CH2— (a-3), —CH2—O— (a-4), —CH2—CH2—O— (a-5), —CH2—S— (a-6), —CH2—CH2—S— (a-7), —CH═N— (a-8), —N═N— (a-9), or —CO—NH— (a-10);
wherein optionally one hydrogen atom may be replaced by C1-4alkyl or Ar1;
R1 and R2 each independently are hydrogen, hydroxy, halo, cyano, C1-6alkyl, trihalomethyl trihalomethoxy, C2-6alkenyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy, C1-6alkyloxycarbonyl, aminoC1-6alkyloxy, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, Ar2, Ar2—C1-6alkyl, Ar2-oxy, Ar2—C1-6alkyloxy; or when on adjacent positions R1 and R2 taken together may form a bivalent radical of formula
—O—CH2—O— (b-1), —O—CH2—CH2—O— (b-2), —O—CH═CH— (b-3), —O—CH2—CH2— (b-4), —O—CH2—CH2—CH2— (b-5), or —CH═CH—CH═CH— (b-6);
R3 and R4 each independently are hydrogen, halo, cyano, C1-6alkyl, C1-6alkyloxy, Ar3-oxy, C1-6alkylthio, di(C1-6alkyl)amino, trihalomethyl, trihalomethoxy, or when on adjacent positions R3 and R4 taken together may form a bivalent radical of formula
—O—CH2—O— (C-1), —O—CH2—CH2—O— (c-2), or —CH═CH—CH═CH— (c-3);
R5 is a radical of formula
13
wherein
R13 is hydrogen, halo, Ar4, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, C1-6alkyloxycarbonyl, C1-6alkylS(O)C1-6alkyl or C1-6alkylS(O)2C1-6alkyl;
R14 is hydrogen, C1-16alkyl or di(C 14alkyl)aminosulfonyl;
R6 is hydrogen, hydroxy, halo, C1-6alkyl, cyano, haloC1-6alkyl, hydroxyC1-6alkyl, cyanoC1-6alkyl, aminoC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkylthioC1-6alkyl, aminocarbonylC1-6alkyl, C1-6alkyloxycarbonylC1-6alkyl, C1-6alkylcarbonyl-C1-6alkyl, C1-6alkyloxycarbonyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, Ar5, Ar5-C1-6alkyloxyC1-6alkyl; or a radical of formula
—O—R7 (e-1), —S—R7 (e-2), —N—R8R9 (e-3),
wherein
R7 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, Ar6, Ar6—C1-6alkyl, C1-6alkyloxycarbonylC1-6alkyl, or a radical of formula -Alk-OR10 or -Alk-NR11R12;
R8 is hydrogen, C1-6alkyl, Ar7 or Ar7-C1-6alkyl;
R9 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylaminocarbonyl, Ar8, Ar8-C1-6alkyl, C1-6alkylcarbonylC1-6alkyl, Ar8-carbonyl, Ar8-C1-6alkylcarbonyl, aminocarbonylcarbonyl, C1-6alkyloxyC1-6alkylcarbonyl, hydroxy, C1-6alkyloxy, aminocarbonyl, di(C -6alkyl)aminoC1-6alkylcarbonyl, amino, C1-6alkylamino, C1-6alkylcarbonylamino, or a radical or formula -Alk-OR10 or -Alk-NR11R12;
wherein
Alk is C1-6alkanediyl;
R10 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, hydroxyC1-6alkyl, Ar9 or Ar9-C1-6alkyl;
R11 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, Ar10 or
Ar10—C1-6alkyl;
R12 is hydrogen, C1-6alkyl, Ar11 or Ar11—C1-6alkyl; and
Ar1 to Ar11 are each independently selected from phenyl; or phenyl substituted with halo, C1-6alkyl, C1-6alkyloxy or trifluoromethyl.
14
the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein
the dotted line represents an optional bond;
X is oxygen or sulfur;
R1 and R2 each independently are hydrogen, hydroxy, halo, cyano, C1-6alkyl, trihalomethyl, trihalomethoxy, C2-6alkenyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy, C1-6alkyloxycarbonyl, aminoC1-6alkyloxy, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, Ar1, Ar1C1-6alkyl, Ar1oxy or Ar1C1-6alkyloxy;
R3 and R4 each independently are hydrogen, halo, cyano, C1-6alkyl, C1-6alkyloxy, Ar1oxy, C1-6alkylthio, di(C1-6alkyl)amino, trihalomethyl or trihalomethoxy;
R5 is hydrogen, halo, C1-6alkyl, cyano, haloC1-6alkyl, hydroxyC1-6alkyl, cyanoC1-6alkyl, aminoC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkylthioC1-6alkyl, aminocarbonylC1-6alkyl, C1-16alkyloxycarbonylC1-6alkyl, C1-6alkylcarbonyl-C1-6alkyl, C1-6alkyloxycarbonyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, Ar1, Ar1C1-6alkyloxyC1-6alkyl; or a radical of formula
—O—R10 (a-1), —S—R10 (a-2), —N—R11R12 (a-3),
wherein
R10 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, Ar1, Ar1C1-6alkyl, C1-6alkyloxycarbonylC1-6alkyl, or a radical of formula -Alk-OR13 or -Alk-NR14R15;
R11 is hydrogen, C1-6alkyl, Ar1 or Ar1C1-6alkyl;
R12 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylaminocarbonyl, Ar1, Ar1C1-6alkyl, C1-6alkylcarbonyl-C1-6alkyl, Ar1carbonyl, Ar1C1-6alkylcarbonyl, aminocarbonylcarbonyl, C1-6alkyloxyC1-6alkylcarbonyl, hydroxy, C1-6alkyloxy, aminocarbonyl, di(C1-6alkyl)aminoC1-6alkylcarbonyl, amino, C1-6alkylamino, C1-16alkylcarbonylamino, or a radical or formula -Alk-OR13 or -Alk-NR14R15;
wherein
Alk is C1-6alkanediyl;
R13 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, hydroxyC1-16alkyl, Ar1 or Ar1C1-6alkyl;
R14 is hydrogen, C1-6alkyl, Ar1 or Ar1C1-6alkyl;
R15 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, Ar1 or Ar1C1-16alkyl;
R6 is a radical of formula
15
wherein
R16 is hydrogen, halo, Ar1, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, C1-6alkyloxycarbonyl, C1-6alkylthioC1-6alkyl, C1-6alkylS(O)C1-6alkyl or C1-6alkylS(O)2C 16alkyl;
R17 is hydrogen, C1-6alkyl or di(C1-4alkyl)aminosulfonyl;
R7 is hydrogen or C 16alkyl provided that the dotted line does not represent a bond;
R8 is hydrogen, C 16alkyl or Ar2CH2 or Het1CH2;
R9 is hydrogen, C1-6alkyl , C1-6alkyloxy or halo; or
R8 and R9 taken together to form a bivalent radical of formula
—CH═CH— (c-1), —CH2—CH2— (c-2), —CH2—CH2—CH2— (c-3), —CH2—O— (c-4), or —CH2—CH2—O— (c-5);
Ar1 is phenyl; or phenyl substituted with 1 or 2 substituents each independently selected from halo, C1-6alkyl, C1-6alkyloxy or trifluoromethyl;
Ar2 is phenyl; or phenyl substituted with 1 or 2 substituents each independently selected from halo, C 16alkyl, C1-6alkyloxy or trifluoromethyl; and
Het1 is pyridinyl; pyridinyl substituted with 1 or 2 substituents each independently selected from halo, C1-6alkyl, C1-6alkyloxy or trifluoromethyl and
16
or the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein
═X1—X2—X3— is a trivalent radical of formula
4 ═N—CR6═CR7— (x-1), ═N—N═CR6— (x-2), ═N—NH—C(═O)— (x-3), ═N—N═N— (x-4), ═N—CR6═N— (x-5), ═CR6—CR7═CR8— (x-6), ═CR6—N═CR7— (x-7), ═CR6—NH—C(═O)— (x-8), or ═CR6—N═N— (x-9);
wherein each R6, R7 and R8 are independently hydrogen, C1-4alkyl, hydroxy, C1-4alkyloxy, aryloxy, C1-4alkyloxycarbonyl, hydroxyC1-4alkyl, C1-4alkyloxyC1-4alkyl, mono- or di(C1-4alkyl)aminoC1-4alkyl, cyano, amino, thio, C1-4alkylthio, arylthio or aryl;
>Y1—Y2— is a trivalent radical of formula
>CH—CHR9— (y-1), >C═N— (y-2), >CH—NR9— (y-3), or >C═CR9— (y-4);
wherein each R9 independently is hydrogen, halo, halocarbonyl, aminocarbonyl, hydroxyC1-4alkyl, cyano, carboxyl, C1-4alkyl, C1-4alkyloxy, C1-4alkyloxyC1-4alkyl, C1-4alkyloxycarbonyl, mono- or di(C1-4alkyl)amino, mono- or di(C1-4alkyl)aminoC1-4alkyl, aryl;
r and s are each independently 0, 1, 2, 3, 4 or 5;
t is 0, 1, 2 or 3;
each R1 and R2 are independently hydroxy, halo, cyano, C1-6alkyl, trihalomethyl, trihalomethoxy, C2-6alkenyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1alkylthio, C1-6alkyloxyC1-6alkyloxy, C1-6alkyloxycarbonyl, aminoC1-6alkyloxy, mono- or di(C1-6alkyl)amino, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, aryl, arylC1-6alkyl, aryloxy or arylC1-6alkyloxy, hydroxycarbonyl, C1-6alkyloxycarbonyl, aminocarbonyl, aminoC1-6alkyl, mono- or di(C1-6alkyl)aminocarbonyl, mono- or di(C1-6alkyl)aminoC1-6alkyl; or
two R1 or R2 substituents adjacent to one another on the phenyl ring may independently form together a bivalent radical of formula
—O—CH2—O— (a-1), —O—CH2—CH2—O— (a-2), —O═CH═CH— (a-3), —O—CH2—CH2— (a-4), —O—CH2—CH2—CH2— (a-5), or —CH═CH—CH═CH— (a-6);
R3 is hydrogen, halo, C1-6alkyl, cyano, haloC1-6alkyl, hydroxyC1-6alkyl, cyanoC1-6alkyl, aminoC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkylthioC1-6alkyl, aminocarbonylC1-6alkyl, hydroxycarbonyl, hydroxycarbonylC1-6alkyl, C1-6alkyloxycarbonylC1-6alkyl, C1-6alkylcarbonylC1-6alkyl, C1-6alkyloxycarbonyl, aryl, arylC1-6alkyloxyC1-6alkyl, mono- or di(C, alkyl)aminoC1-6alkyl;
or a radical of formula
—O—R10 (b-1), —S—R10 (b-2), —NR11R12 (b-3),
wherein
R10 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, aryl, arylC1-6alkyl, C1-6alkyloxycarbonylC1-6alkyl, or a radical of formula -Alk-OR13 or -Alk-NR14R15;
R11 is hydrogen, C1-6alkyl, aryl or arylC1-6alkyl;
R12 is hydrogen, C1-6alkyl, aryl, hydroxy, amino, C1-6alkyloxy, C1-6alkylcarbonylC1-6alkyl, arylC1-6alkyl, C1-6alkylcarbonylamino, mono- or di(C1-6alkyl)amino, C1-6alkylcarbonyl, aminocarbonyl, arylcarbonyl, haloC1-6alkylcarbonyl, arylC1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkyloxyC1-6alkylcarbonyl, mono- or di(C1-6alkyl)aminocarbonyl wherein the alkyl moiety may optionally be substituted by one or more substituents independently selected from aryl or C1-3alkyloxycarbonyl, aminocarbonylcarbonyl, mono- or di(C1-6alkyl)aminoC1-6alkylcarbonyl, or a radical or formula -Alk-OR13 or -Alk-NR14R15;
wherein
Alk is C1-6alkanediyl;
R13 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, hydroxyC1-6alkyl, aryl or arylC1-6alkyl;
R14 is hydrogen, C1-6alkyl, aryl or arylC1-6alkyl;
R15 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, aryl or arylC1-6alkyl;
R4 is a radical of formula
17
wherein R16 is hydrogen, halo, aryl, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, mono- or di(C1-4alkyl)amino, hydroxycarbonyl, C1-6alkyloxycarbonyl, C1-6alkylthioC1-6alkyl, C1-6alkylS(O)C1-6alkyl or C1-6alkylS(O)2C1-6alkyl;
R16 may also be bound to one of the nitrogen atoms in the imidazole ring of formula (c-1) or (c-2), in which case the meaning of R16 when bound to the nitrogen is limited to hydrogen, aryl, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkyloxycarbonyl, C1-6alkylS(O)C1-6alkyl or C1-6alkylS(O)2C1-6alkyl;
R17 is hydrogen, C1-6alkyl, C1-6alkyloxyC1-6alkyl, arylC1-6alkyl, trifluoromethyl or di(C1-4alkyl)aminosulfonyl;
R5 is C1-6alkyl , C1-6alkyloxy or halo; aryl is phenyl, naphthalenyl or phenyl substituted with 1 or more substituents each independently selected from halo, C1-6alkyl, C1-6alkyloxy or trifluoromethyl: and two or more further anti-cancer agents.

### Claim 2 (depends on 1)

A combination as claimed in claim 1 wherein the farnesyl protein transferase inhibitor is a compound of formula (I) wherein X is oxygen and the dotted line represents a bond.

### Claim 3 (depends on 1, 2)

A combination as claimed in claim 1 or claim 2 wherein the farnesyl protein transferase inhibitor is a compound of formula (I) wherein R1 is hydrogen, C1-6alkyl, C1-6alkyloxyC1-6alkyl or mono- or di(C1-6alkyl)aminoC1-6alkyl and wherein R3 is hydrogen and R2 is halo, C1-6alkyl, C2-6alkenyl, C1-6alkyloxy, trihalomethoxy or hydroxyC1-6alkyloxy.

### Claim 4

A combination as claimed in any of the preceding claims wherein the farnesyl protein transferase inhibitor is a compound of formula (I) wherein R8 is hydrogen, hydroxy, haloC1-6alkyl, hydroxyC1-6alkyl, cyanoC1-6alkyl, C1-6alkyloxycarbonylC1-6alkyl, imidazolyl, or a radical of formula NR11R12 wherein R11 is hydrogen or C1-2alkyl and R12 is hydrogen, C1-6alkyl, C1-6alkyloxy, C1-6alkyloxyC1-6alkylcarbonyl, hydroxy, or a radical of formula -Alk2-OR13 wherein R13 is hydrogen or C1-6alkyl.

### Claim 5 (depends on 1)

A combination as claimed in claim 1 wherein the farnesyl transferase inhibitor is selected from:
4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)-methyl]-1-methyl-2(1H)-quinolinone,
6-[amino(4-chlorophenyl)-1-methyl-1H-imidazol-5-ylmethyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone;
6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethoxyphenyl)-1-methyl-2(1H)-quinolinone;
6-[(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethoxyphenyl)-1-methyl-2(1H)-quinolinone monohydrochloride.monohydrate;
6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethoxyphenyl)-1-methyl-2(1H)-quinolinone, and
6-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-4-(3-propylphenyl)-2(1H)-quinolinone; a stereoisomeric form thereof or a pharmaceutically acceptable acid or base addition salts thereof.

### Claim 6 (depends on 1)

A combination as claimed in claim 1 wherein the farnesyl transferase inhibitor is (+)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chloro-phenyl)-1-methyl-2(1H)-quinolinone; or a pharmaceutically acceptable acid addition salt thereof.

### Claim at position 7 (depends on 1)

7 A combination as claimed in claim 1 wherein the farnesyl protein transferase inhibitor is a compound of formula (IX) wherein ═X1—X2—X3 is a trivalent radical of formula (x-2), (x-3) or (x-4), >Y1—Y2 is a trivalent radical of formula (y-2), (y-3) or (y-4), r and s are 1, t is 0, R1 is halo, preferably chloro, and most preferably 3-chloro or R1 is C1-4alkyl, preferably 3-methyl, R2 is halo, preferably chloro, and most preferably 4-chloro, R3 is a radical of formula (b-1) or (b-3), R4 is a radical of formula (c-2), R6 is C1-4alkyl, R9 is hydrogen, R10 and R11 are hydrogen and R12 is hydrogen or hydroxy.

### Claim 8 (depends on 1)

A combination as claimed in claim 1 wherein the farnesyl protein transferase inhibitor is 5-(3-chlorophenyl)-α-(4-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]quinazoline-7-methanamine or a pharmaceutically acceptable acid addition salt thereof.

### Claim 9

A combination as claimed in any of the preceding claims in which the two or more further anti-cancer agents are independently selected from platinum coordination compounds, taxane compounds, camptothecin compounds, anti-tumour vinca alkaloids, anti-tumor nucleoside derivatives, nitrogen mustard or nitrosourea alkylating agents, anti-tumor anthracycline derivatives, trastzumab and anti-tumor podophyllotoxin derivatives.

### Claim 10 (depends on 9)

A combination as claimed in claim 9 in which platinum coordination compounds is cisplatin or carboplatin.

### Claim 11 (depends on 9)

A combination as claimed in claim 9 in which the taxane compound is paclitaxel or docetaxel.

### Claim 12 (depends on 9)

A combination as claimed in claim 9 in which the anti-tumor vinca alkaloid is vinblastine, vincristine or vinorelbine.

### Claim 13 (depends on 9)

A combination as claimed in claim 9 in which the anti-tumor nucleoside derivative is 5-fluorouracil, gemcitabine or capecitabine.

### Claim 14 (depends on 9)

A combination as claimed in claim 9 in which the nitrogen mustard or nitrosourea alkylating agent is cyclophosphamide, chlorambucil, carmustine or lomustine.

### Claim 15 (depends on 9)

A combination as claimed in claim 9 in which the anti-tumor anthracycline derivative is daunorubicin, doxorubicin or idarubicin.

### Claim 16 (depends on 9)

A combination as claimed in claim 9 in which the anti-tumor podophyllotoxin derivative is etoposide and teniposide.

### Claim 17 (depends on 1)

A combination as claimed in any of the preceding claims in the form of a pharmaceutical composition comprising a farnesyl transferase inhibitor selected from compounds of formulae (I), (II), (III), (IV), (V), (VI), (VII), (VIM and (IX) (as defined in claim 1) and two or more further anti-cancer agents, together with one or more pharmaceutical carriers.

### Claim 18

A combination as claimed in any of the preceding claims for use in medical therapy.

### Claim 19 (depends on 18)

A combination as claimed in claim 18 for inhibiting the growth of tumor cells.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

Use of a combination as claimed in any of claims 1 to 19 in the manufacture of a pharmaceutical composition for inhibiting the growth of tumor cells.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A method of inhibiting the growth of tumor cells in a human subject which comprises administering to the subject an effective amount of a combination as claimed in any of claims 1 to 19.
